top of page
Insights
Q&A: Dr. Toby Maher, MD, MSc, PhD, FRCP
Dr. Maher is the Professor of Medicine and Director of Interstitial Lung Disease at the Keck School of Medicine of USC University of Southern California Dr. Maher has spent over 20 years specialising in the management of interstitial lung disease. Since June 2020 he has been Director of ILD at Keck Medicine of University of Southern California. He previously ran the ILD unit at Royal Brompton Hospital, London and was a Professor of ILD at Imperial College, London. His researc
Q&A: Naftali Kaminski, MD
Dr. Kaminski is the the Boehringer-Ingelheim Endowed Professor of Internal Medicine and Chief of Pulmonary, Critical Care and Sleep Medicine, at Yale School of Medicine The following questions were submitted from Three Lakes 12-20 subscribers and followers as a part of our Ask the Expert series, where we provide a forum to industry professionals to widen access and education from those who are actively working towards the treatment and future of pulmonary fibrosis. The existi
Q&A: Dr. Anna Podolanczuk, MD
Dr. Podolanczuk is the Co-Director of the Weill Cornell Interstitial Lung Disease Program The following questions were submitted from Three Lakes 12-20 subscribers and followers as a part of our Ask the Expert series, where we provide a forum to industry professionals to widen access and education from those who are actively working towards the treatment and future of pulmonary fibrosis. The existing drugs are antifibrotics, and slow disease but do not stop progression. In te
bottom of page